Novartis announced today that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”